Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AG 2195

Drug Profile

AG 2195

Alternative Names: AG-2195

Latest Information Update: 14 Aug 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corixa Corporation
  • Class
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Myasthenia gravis

Most Recent Events

  • 17 May 2005 No development reported - Preclinical for Myasthenia gravis in Europe (unspecified route)
  • 30 May 2003 Beaufour-Ipsen is now called Ipsen
  • 22 Jan 2002 Beaufour Ipsen has acquired a licence for worldwide development and marketing of AG 2195 from Corixa Corporation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top